We are live on ! Find out more
SLN icon

Silence Therapeutics
SLN

6 hedge funds and large institutions have $55.9M invested in Silence Therapeutics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,438,535% more capital inflows, than outflows

Capital inflows: $48.8M | Capital outflows: $2K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding

Funds holding: 3 → 6 (+3)

6.7% more ownership

Funds ownership: 1.81% → 8.51% (+6.7%)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.11%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BVF Inc
BVF Inc
California
+$16.2M
2
Lombard Odier Asset Management (USA)
Lombard Odier Asset Management (USA)
New York
+$16M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.8M
4
Consonance Capital Management
Consonance Capital Management
New York
+$5.41M
5
Morgan Stanley
Morgan Stanley
New York
+$197K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2K

SLN Hedge Fund Activity: Q1 2021 in Review

6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2021, worth a combined $55.9M — up 448% from $10.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SLN positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $16.2M. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.

  • 6 institutional investors held Silence Therapeutics (SLN) as of Q1 2021, up from 3 in Q4 2020.
  • Funds reported $55.9M of Silence Therapeutics stock for Q1 2021, up 448% quarter-over-quarter.
  • 4 funds opened new Silence Therapeutics positions in Q1 2021 and 1 closed out, a net change of +3 holders.
  • The largest Silence Therapeutics buyer in Q1 2021 was BVF Inc, an estimated $16.2M added.
  • The largest Silence Therapeutics seller in Q1 2021 was UBS Group, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2021.